Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
FGFR2-BICC1 fusion
i
Other names:
FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor 2, BICC1, BicC Family RNA Binding Protein 1, Protein Bicaudal C Homolog 1, FGFR2-BICC1 Fusion Kinase Protein, Bicaudal C Homolog 1 (Drosophila), Bicaudal C Homolog 1, CYSRD, Bic-C, BICC
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2263
;
80114
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BAP1 mutation + FGFR2 fusion (1)
FGFR2 underexpression + FGFR3 mutation (1)
IDH1 mutation + FGFR2 fusion (1)
IDH1 mutation + FGFR2 rearrangement (1)
NOTCH1 positive + FGFR2 mutation (1)
PBRM1 mutation + FGFR2 fusion (1)
TP53 mutation + FGFR2 fusion (1)
FGFR2 K660N + TP53 deletion (0)
BAP1 mutation + FGFR2 fusion (1)
FGFR2 underexpression + FGFR3 mutation (1)
IDH1 mutation + FGFR2 fusion (1)
IDH1 mutation + FGFR2 rearrangement (1)
NOTCH1 positive + FGFR2 mutation (1)
PBRM1 mutation + FGFR2 fusion (1)
TP53 mutation + FGFR2 fusion (1)
FGFR2 K660N + TP53 deletion (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2-BICC1 fusion
Urothelial Cancer
FGFR2-BICC1 fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
futibatinib
Sensitive: C3 – Early Trials
futibatinib
Sensitive
:
C3
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
infigratinib + PD173074
Sensitive: C3 – Early Trials
infigratinib + PD173074
Sensitive
:
C3
FGFR2-BICC1 fusion
Endometrial Cancer
FGFR2-BICC1 fusion
Endometrial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
infigratinib
Resistant: C4 – Case Studies
infigratinib
Resistant
:
C4
infigratinib
Resistant: C4 – Case Studies
infigratinib
Resistant
:
C4
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
sorafenib
Sensitive: C4 – Case Studies
sorafenib
Sensitive
:
C4
sorafenib
Sensitive: C4 – Case Studies
sorafenib
Sensitive
:
C4
FGFR2-BICC1 fusion
Cholangiocarcinoma
FGFR2-BICC1 fusion
Cholangiocarcinoma
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
pembrolizumab + pemigatinib
Sensitive
:
C4
pembrolizumab + pemigatinib
Sensitive: C4 – Case Studies
pembrolizumab + pemigatinib
Sensitive
:
C4
FGFR2-BICC1 fusion
Biliary Tract Cancer
FGFR2-BICC1 fusion
Biliary Tract Cancer
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
FGFR inhibitor
Sensitive: D – Preclinical
FGFR inhibitor
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login